Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.50.

A number of brokerages have commented on TARA. Scotiabank began coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price objective for the company in a report on Thursday, May 22nd. Cantor Fitzgerald started coverage on Protara Therapeutics in a research report on Friday, March 14th. They set an "overweight" rating for the company. HC Wainwright restated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a research report on Monday, April 28th. Finally, Lifesci Capital started coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price target on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. acquired a new position in Protara Therapeutics in the 1st quarter valued at about $64,000. HBK Investments L P acquired a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $106,000. Squarepoint Ops LLC acquired a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $110,000. Dimensional Fund Advisors LP acquired a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $111,000. Finally, American Century Companies Inc. bought a new stake in shares of Protara Therapeutics during the 1st quarter worth approximately $154,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Protara Therapeutics Trading Down 3.4%

Shares of TARA stock opened at $2.88 on Monday. The company has a market cap of $111.11 million, a price-to-earnings ratio of -1.67 and a beta of 1.34. The stock has a 50 day simple moving average of $3.30 and a 200-day simple moving average of $4.10. Protara Therapeutics has a 12-month low of $1.60 and a 12-month high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.18. On average, equities analysts forecast that Protara Therapeutics will post -3.32 earnings per share for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.